Royal Bank of Canada’s LB Pharmaceuticals LBRX Stock Holding History

Royal Bank of Canada’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-767	Closed	-$17K	–	7926
2025 Q4	$17K	Buy	+767	New	+$13.4K	﹤0.01%	6157

Other funds holding LBRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Royal Bank of Canada's LBRX Position: Q1 2026 in Review

Royal Bank of Canada sold out of LB Pharmaceuticals (LBRX) in Q1 2026, closing a stake of 767 shares — an estimated $17K sold.

Royal Bank of Canada first reported a position in LBRX in Q4 2025 and held it in 1 quarter. The position peaked at $17K in Q4 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

Royal Bank of Canada reported no remaining LB Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Royal Bank of Canada sold 767 LB Pharmaceuticals shares in Q1 2026, an estimated $17K.
Royal Bank of Canada first reported a position in LB Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Royal Bank of Canada's LB Pharmaceuticals position peaked at $17K in Q4 2025.
77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.